Abstract
Although the 5q- syndrome is common in both de novo and treatment related myelodysplastic syndrome (MDS) and the World Health Organization defined 5q- syndrome as a specific type of MDS, it is less common in acute myelogenous leukemia (AML). Recently, it was suggested that AML with diploidy/tetraploidy and/or 5q alterations may be associated with the cryptic translocation, t(7;21)(p22;q22) resulting in RUNX1-USP42 gene fusion and this association may have been underestimated. Here, we report another case of de novo AML with cryptic t(7;21)(p22;q22) associated with a 5q deletion.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 30-34 |
| Number of pages | 5 |
| Journal | Cancer Genetics |
| Volume | 262-263 |
| DOIs | |
| State | Published - Apr 2022 |
Keywords
- 5q abnormalities
- Acute myeloid leukemia
- Fluorescence in situ hybridization
- Minimal differentiation
- t(7, 21)
ASJC Scopus subject areas
- Genetics
- Molecular Biology
- Cancer Research
Fingerprint
Dive into the research topics of 'Is 5q deletion in de novo Acute Myelogenous Leukemia (AML) with excess blasts a surrogate marker for the cryptic t(7;21)(p22;q22)? A case report and review of literature'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS